Floatz logo

Anti-Cd19/Cd20/Cd22 Car T-Cells

Refractory Chronic Lymphocytic Leukemia

Sumithira VasuCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Refractory Chronic Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
Benadryl
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BBB
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BBB
Therapeutic Allogeneic Lymphocytes
University of Chicago
Phase 2BB
Flavopiridol
National Cancer Institute (NCI)
Phase 2BB
Everolimus
OHSU Knight Cancer Institute
Phase 2BB

View all 32 →

Same molecule, other indications

Anti-Cd19/Cd20/Cd22 Car T-Cells is also rated in:

Recurrent B Acute Lymphoblastic LeukemiaDormant
CC
Indicative ·
43 / 100
View asset →
Recurrent B-Cell Prolymphocytic LeukemiaDormant
CC
Indicative ·
43 / 100
View asset →
Recurrent Acute Lymphoblastic LeukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →